ストックスクリーナーアプリを入手
13.48
28.26%
2.97
プレマーケット:
13.99
0.51
+3.78%
前日終値:
$10.51
開ける：
$12.98
24時間の取引高:
2.92M
Relative Volume:
4.49
時価総額：
$853.57M
収益：
$202.09M
当期純損益:
$-61.69M
株価収益率:
-12.48
EPS:
-1.08
ネットキャッシュフロー:
$-35.64M
1週間 パフォーマンス:
+42.34%
1か月 パフォーマンス:
+23.78%
6か月 パフォーマンス:
+12.71%
1年 パフォーマンス:
+13.76%
1日の値動き範囲:
$12.74
$14.49
1週間の範囲:
$9.64
$14.49
52週間の値動き範囲:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
EOLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
13.48 | 853.57M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 開始されました | Needham | Buy |
| 2022-05-12 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-06 | アップグレード | Mizuho | Neutral → Buy |
| 2021-04-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-24 | ダウングレード | Truist | Buy → Hold |
| 2020-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-02-06 | 再開されました | Mizuho | Buy |
| 2019-11-26 | 開始されました | SVB Leerink | Outperform |
| 2019-09-05 | 再開されました | Mizuho | Buy |
| 2019-06-28 | 開始されました | Wells Fargo | Market Perform |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
すべてを表示
Evolus Inc (EOLS) 最新ニュース
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
Evolus projects robust 2025 growth with upcoming product launches - MSN
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates - Benzinga
Evolus Shares Surge 34% on Record Q4 Revenue and FDA Approval Ex - GuruFocus.com
Evolus (NASDAQ:EOLS) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why - MSN
Evolus (NASDAQ:EOLS) Shares Gap UpTime to Buy? - MarketBeat
Evolus announces Q4 preliminary unaudited net revenue of $79M - MSN
Evolus shares surge on strong Q4 results and upbeat 2025 outlook - MSN
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
Evolus Shares Rise on Jump in Revenue - MarketWatch
Evolus, Inc. Provides Financial Guidance for the Full Year of 2025 -January 21, 2025 at 08:00 am EST - Marketscreener.com
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Trend Tracker for (EOLS) - Stock Traders Daily
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 (NASDAQ:EOLS) - Seeking Alpha
Evolus (NASDAQ:EOLS) Hits New 1-Year LowHere's Why - MarketBeat
Possible Bearish Signals With Evolus Insiders Disposing Stock - Simply Wall St
Evolus stock touches 52-week low at $10.23 amid market shifts - Investing.com Nigeria
Evolus (NASDAQ:EOLS) Sets New 52-Week LowHere's What Happened - MarketBeat
EVOLUS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased E - PR Newswire
(EOLS) Technical Data - Stock Traders Daily
Barclays PLC Grows Stake in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27 - GuruFocus.com
Evolus CFO Sandra Beaver sells shares worth $17,211 By Investing.com - Investing.com Australia
Evolus chief medical officer sells shares worth $24,438 By Investing.com - Investing.com Australia
Evolus chief medical officer sells shares worth $24,438 - Investing.com India
Evolus CFO Sandra Beaver sells shares worth $17,211 - Investing.com India
Evolus, Inc. (NASDAQ:EOLS) CFO Sells $17,208.10 in Stock - MarketBeat
Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock - MarketBeat
Evolus CEO David Moatazedi sells $113,966 in stock By Investing.com - Investing.com Nigeria
Evolus CEO David Moatazedi sells $113,966 in stock - Investing.com
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by State Street Corp - MarketBeat
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability - Yahoo Finance
Lord Abbett & CO. LLC Acquires 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Stock Options Galore! Discover Evolus’ Latest Move - Jomfruland.net
(EOLS) On The My Stocks Page - Stock Traders Daily
Evolus Expands Team with Strategic Equity Incentives Package for 20 New Hires - StockTitan
Evolus's SWOT analysis: aesthetics firm's stock poised for growth By Investing.com - Investing.com South Africa
Evolus's SWOT analysis: aesthetics firm's stock poised for growth - Investing.com
Evolus Inc (EOLS) 財務データ
収益
当期純利益
現金流量
EPS
2.14%
大文字化:
|
ボリューム (24 時間):